代谢综合征对结直肠癌患者术后并发症及长期生存的影响。
The effect of metabolic syndrome on postoperative complications and long-term survival of patients with colorectal cancer.
作者信息
Zhu Ce, Mao Chenchen, Cai Wentao, Zheng Jingwei, Yang Hui, You Tao, Chen Jian, Yu Yaojun, Shen Xian, Li Liyi
机构信息
Department of Gastrointestinal Surgery, The Second Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Department of Microbiology and Immunology, School of Basic Medical Sciences, Institute of Molecular Virology and Immunology, Wenzhou Medical University, Zhejiang, China.
出版信息
Front Oncol. 2023 Jun 26;13:1036458. doi: 10.3389/fonc.2023.1036458. eCollection 2023.
BACKGROUND
Metabolic syndrome (MetS) is associated with poor prognosis in many cancers. However, the relationship between metabolic syndrome and overall survival (OS) in patients with colorectal cancer (CRC) remains unclear. We aimed to comprehensively analyze whether MetS could affect postoperative complications and long-term survival in patients with CRC.
METHODS
We included patients who underwent CRC resection at our center between January 2016 and December 2018. Bias was reduced through propensity score matching analysis. Patients with CRC were divided into the MetS and non-MetS groups based on whether they had MetS. Univariate and multivariate analyses were used to identify risk factors affecting OS.
RESULTS
We included 268 patients; among them, 120 were included for further analysis after propensity score matching. There were no significant between-group differences in the clinicopathological features after matching. Compared with the non-MetS group, the MetS group had a shorter OS (P = 0.027); however, there was no significant between-group difference in postoperative complications. Multivariate analysis revealed that MetS (hazard ratio [HR] = 1.997, P = 0.042), tumor-node-metastasis stage (HR = 2.422, P = 0.003), and intestinal obstruction (HR = 2.761, P = 0.010) were independent risk factors for OS.
CONCLUSIONS
MetS affects the long-term survival of patients with CRC without affecting postoperative complications.
背景
代谢综合征（MetS）与许多癌症的不良预后相关。然而，代谢综合征与结直肠癌（CRC）患者总生存期（OS）之间的关系仍不明确。我们旨在全面分析MetS是否会影响CRC患者术后并发症及长期生存。
方法
纳入2016年1月至2018年12月在本中心接受CRC切除术的患者。通过倾向评分匹配分析减少偏倚。根据是否患有MetS将CRC患者分为MetS组和非MetS组。采用单因素和多因素分析确定影响OS的危险因素。
结果
共纳入268例患者；其中，120例在倾向评分匹配后纳入进一步分析。匹配后组间临床病理特征无显著差异。与非MetS组相比，MetS组的OS较短（P = 0.027）；然而，组间术后并发症无显著差异。多因素分析显示，MetS（风险比[HR] = 1.997，P = 0.042）、肿瘤-淋巴结-转移分期（HR = 2.422，P = 0.003）和肠梗阻（HR = 2.761，P = 0.010）是OS的独立危险因素。
结论
MetS影响CRC患者的长期生存，但不影响术后并发症。
Zotero 插件